Intra-articular therapy in hip osteoarthritis

Migliore, Alberto; Anichini, Silvia

doi:10.11138/ccmbm/2017.14.1.179

Cited by 8 publications

(8 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among the total OA cases, articulatio coxae, also named as hip joint, is the second most frequently involved joint, resulting in chronic pain in patients’ outer hip, groin, and sometimes extends to the knee, and the pain often aggravates as the disease progresses (Aresti et al 2016 ). Therapeutic modalities for hip OA patients include physical exercise, weight management, non-steroidal anti-inflammatory drugs (NSAIDs) or other analgesics, sodium hyaluronate injection and surgery (Migliore and Anichini 2017 ; Murphy et al 2016 ; Skou and Roos 2019 ). Among all the treatment options mentioned above, total hip arthroplasty (THA) surgery is the gold standard for hip OA patients with severe disease conditions with satisfactory efficacy in improving the function of hip joint (Shon et al 2019 ).…”

Section: Introductionmentioning

confidence: 99%

Preoperative meloxicam versus postoperative meloxicam for pain control, patients’ satisfaction and function recovery in hip osteoarthritis patients who receive total hip arthroplasty: a randomized, controlled study

Ren

Yan

et al. 2020

Inflammopharmacol

View full text Add to dashboard Cite

This study aimed to compare the analgesic effect, patients' satisfaction, tolerance and hip-joint function recovery by preoperative meloxicam versus postoperative meloxicam in treating hip osteoarthritis (OA) patients receiving total hip arthroplasty (THA). 132 hip OA patients who underwent THA surgery were allocated into postoperative analgesia (POST) and preoperative analgesia (PRE) groups at a 1:1 ratio. In the PRE group, patients took meloxicam 15 mg at 24 h pre-operation, 7.5 mg at 4 h, 24 h, 48 h and 72 h post-operation; in the POST group, patients received meloxicam 15 mg at 4 h post-operation, then 7.5 mg at 24 h, 48 h and 72 h post-operation. Furthermore, postoperative pain, consumption of patient-controlled analgesia (PCA), overall satisfaction and adverse events were evaluated within 96 h post-operation; meanwhile, Harris hip score was assessed within 6 months post-operation. Pain VAS at rest at 6 h, 12 h, 24 h, and pain VAS at passive movement at 6 h, 12 h were decreased in PRE group compared to POST group. In addition, additional consumption of PCA and the total consumption of PCA were both reduced in PRE group compared to POST group. Additionally, overall satisfaction in PRE group was higher at 24 h, 48 h and 72 h compared to POST group. While Harris hip score was of no difference between POST group and PRE group at M3 or M6. Besides, no difference in adverse events incidence was found between the two groups. In conclusion, preoperative meloxicam achieves better efficacy and similar tolerance compared to postoperative meloxicam in hip OA patients post THA.

show abstract

Section: Introductionmentioning

confidence: 99%

Preoperative meloxicam versus postoperative meloxicam for pain control, patients’ satisfaction and function recovery in hip osteoarthritis patients who receive total hip arthroplasty: a randomized, controlled study

Ren

Yan

et al. 2020

Inflammopharmacol

View full text Add to dashboard Cite

show abstract

“…As mentioned above, a placebo must be devoid of adverse effects; otherwise, it is called pseudo-placebo [9]. In particular, the intra-articular therapy of hip osteoarthritis is associated with adverse events due to the proximity of important anatomical structures (RU2396961C1) [84,85]. HA is a polymer; according to the law of mass action, its local enrichment would displace the chemical equilibrium toward low-molecular precursors i.e.…”

Section: Glycosaminoglycans For the Treatment Of Osteoarthritismentioning

confidence: 99%

Scientific Papers and Patents on Substances with Unproven Effects. Part 2

Jargin

2020

DDF

View full text Add to dashboard Cite

: Several examples are discussed in this review, where substances without proven effects were proposed for practical use within the scope of evidence-based medicines. The following is discussed here: generalizations of the hormesis concept and its use in support of homeopathy; phytoestrogens and soy products potentially having feminizing effects; glycosaminoglycans for the treatment of osteoarthritis and possibilities of their replacement by diet modifications; flavonoids recommended for the treatment of chronic venous insufficiency and varicose veins; acetylcysteine as a mucolytic agent and its questionable efficiency especially by an oral intake; stem cells and cell therapies. In conclusion, placebo therapies can be beneficial and ethically justifiable but it is not a sufficient reason to publish biased information. Importantly, placebo must be devoid of adverse effects, otherwise, it is named pseudo-placebo. Therapeutic methods with unproven effects should be tested in high-quality research shielded from the funding bias. Some issues discussed in this review are not entirely clear, and the arguments provided here can initiate a constructive discussion.

show abstract

“…However, a placebo must have no adverse effects by definition; otherwise it is named pseudoplacebo 72 . In particular, the intra-articular therapy of hip osteoarthritis 73 is burdened by complications due to the proximity of important anatomical structures 74 . HA is a polymer; according to the law of mass action, its local enrichment would displace the chemical equilibrium toward low-molecular precursors i.e.…”

Section: Glycosaminoglicans In Osteoarthritismentioning

confidence: 99%

Placebo in the guise of evidence-based medications

Jargin¹

2020

Arşiv Kaynak Tarama Dergisi

View full text Add to dashboard Cite

Placebo therapy can be beneficial and ethically justifiable; but it is not a sufficient reason to publish biased information. Certain journals are selecting reliable reports but others are publishing biased materials and rejecting criticism. Publication series of questional reliability are sometimes continued without making references to published comments. Theories have been construed for promotion of some drugs and dietary supplements without proven effectiveness. This review is a collection of examples, when substances with unproven effects and unclear action mechanisms are directly or indirectly presented by professional publications as evidence-based medications. Some of the topics might be not completely clarified, so that arguments provided here can induce a constructive discussion.

show abstract

Intra-articular therapy in hip osteoarthritis

Cited by 8 publications

References 13 publications

Preoperative meloxicam versus postoperative meloxicam for pain control, patients’ satisfaction and function recovery in hip osteoarthritis patients who receive total hip arthroplasty: a randomized, controlled study

Preoperative meloxicam versus postoperative meloxicam for pain control, patients’ satisfaction and function recovery in hip osteoarthritis patients who receive total hip arthroplasty: a randomized, controlled study

Scientific Papers and Patents on Substances with Unproven Effects. Part 2

Placebo in the guise of evidence-based medications

Contact Info

Product

Resources

About